In Germany, phage research and application can be traced back to the beginning of the 20th century. However, with the triumphal march of antibiotics around the world, the significance of bacteriophages faded in most countries, and respective research mainly focused on fundamental questions and niche applications. After a century, we pay tribute to the overuse of antibiotics that led to multidrug resistance and calls for new strategies to combat pathogenic microbes. Against this background, bacteriophages came into the spotlight of researchers and practitioners again resulting in a fast growing "phage community". In October 2017, part of this community met at the 1st German Phage Symposium to share their knowledge and experiences. The participants discussed open questions and challenges related to phage therapy and the application of phages in general. This report summarizes the presentations given, highlights the main points of the round table discussion and concludes with an outlook for the different aspects of phage application.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923452 | PMC |
http://dx.doi.org/10.3390/v10040158 | DOI Listing |
Environ Int
December 2024
Department of Oncology and Molecular Medicine, National Institute of Health (Istituto Superiore di Sanità), Rome, Italy(2).
Sci Rep
December 2024
Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Because of their developmental toxicity, some antiseizure medication (ASM) should be avoided during pregnancy. This may lead to discontinuation or switching of ASM after recognition of pregnancy, but some of these changes may be suboptimal. Trends in ASM use at conception were analyzed in 3,763 pregnancies prospectively ascertained by a teratology information service in Germany between 2000 and 2018.
View Article and Find Full Text PDFSupport Care Cancer
December 2024
Pain Therapy Unit, Department of Anaesthesiology and Intensive Care Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89075, Ulm, Germany.
Purpose: The increasing survival rates of oncology patients have led to a corresponding increase in long-time survivors living with chronic cancer-related pain. Data is scarce on the care situation for this distinct clinical entity and on specific therapy requirements, such as interdisciplinary, multimodal pain therapy (IMPT). Our cross-sectional study aimed to assess the current care situation, distinct chronification factors, and optimization potential.
View Article and Find Full Text PDFZ Evid Fortbild Qual Gesundhwes
December 2024
Arbeitsgruppe Data-Driven Innovation, Technische Universität Hamburg (TUHH), Hamburg, Deutschland. Electronic address:
Background: With the introduction of the Digital Healthcare Act (DVG) at the end of 2019, digital health applications (DiGA) were included in the statutory health insurance in Germany. DiGA are digital medical products whose primary function is based on digital technologies. In the definition of the approval process, the term "therapeutic benefit", which is crucial to the evaluation of pharmaceuticals, was expanded to include the broader concept of "positive healthcare effect" ("pVE").
View Article and Find Full Text PDFFront Reprod Health
November 2024
Kinderwunschzentrum Ulm, Ulm, Germany.
Objectives: Endometrial scratching (ES) and/or intravenous intralipid therapy (in cases of increased uterine natural killer cells, uNKs) are still conducted in several fertility centers as "add-on" treatments in patients undergoing ART, although convincing evidence for beneficial effects is lacking.
Study Design: In this retrospective study, associations between ES treatment or additional intralipid therapy and pregnancy and live birth rates of 1,546 patients undergoing 2,821 IVF-/ICSI-treatment cycles with fresh or frozen embryo transfers in a German fertility-center between 1st January 2014 and 31th May 2017 were analyzed.
Results: Overall pregnancy and live birth rates for all 2,821 treatment cycles (468 cycles with ES) were 32.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!